Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a...

Area of Science:

• Oncology
• Biomarker Discovery
• Clinical Trials

Background:

• Limited understanding of up-front biomarker testing's impact on long-term outcomes in advanced or metastatic non-small cell lung cancer (a/mNSCLC).
• Real-world data is crucial for evaluating testing strategies and treatment concordance.

Purpose of the Study:

• To compare overall survival (OS) based on biomarker testing status.
• To assess the impact of guideline-concordant therapy on OS in a/mNSCLC patients.
• To analyze real-world data for treatment decision-making in a/mNSCLC.

Main Methods:

• Retrospective analysis of a large real-world a/mNSCLC electronic healthcare records database.
• Inclusion of patients with nonsquamous a/mNSCLC initiating first-line therapy from January 1, 2015.
• Kaplan-Meier analysis and multivariable Cox proportional hazard modeling to compare OS.

Main Results:

• 88% of patients had at least one biomarker test recorded; 69% were tested before or at first-line treatment initiation.
• Higher hazard of death observed in patients never tested (HR 1.30) or not tested before first-line therapy (HR 1.12).
• Increased hazard of death (HR 1.25) for patients with biomarker-positive disease not receiving guideline-concordant first-line treatment.

Conclusions:

• Up-front biomarker testing is associated with improved survival in a/mNSCLC.
• Guideline-concordant first-line therapy following biomarker testing significantly improves survival outcomes.
• Real-world evidence supports the integration of biomarker testing into treatment decisions for a/mNSCLC.